A literature search: “vaccination of COPD patients” was performed using Medline, the Cochrane Library and other Non-Indexed Citations for this review. This article presents a brief overview of thedifferent studies found, on the new patents, and the future strategies on the field.Moreno...
Immuno- genity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med 2004;98:1187–94. [4] Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccha- ride vaccination. J ...
PCV13 was found safe and immunogenic in BA and COPD patients. Severe adverse reactions were observed in seven patients with cryopyrin-associated periodic syndromes (CAPS) after vaccination with PCV vaccines. The authors expressed concern that other patients with the autoinflammatory disease could also ...
Infections have important adverse consequences for older adults, particularly those who are frail. In this chapter, we review how age and frailty impact immune responses to infections and vaccines, including through immunosenescence and inflammaging. We
It is in Phase III development for COPD. “Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,” said Mike Wells, a pulmonolog...
EP: 4.Patients Most At Risk of Flu EP: 5.Recommended Flu Vaccines for Older Adults Now Viewing EP: 6.Correlation Between Vaccines and Flu Transmissions EP: 7.ACIP Decision Making Process for Flu Recommendations EP: 8.Improving Vaccine Protection Within the Population EP: 9.Choosing a Vacci...
These authorities also state that it may be appropriate to consider periodic re-vaccination of certain high-risk immunocompromised patients, who are likely to have poor initial antibody response and rapid decline of antibodies after vaccination. In addition, re-vaccination with the 23-valent ...
Subgroup analyses of patients hospitalized with COVID-19 pneumonia or death by time after booster demonstrated similar incidence estimates among those aged 65 years or older and with high-risk comorbid conditions but not among those with immunocompromising conditions. Conclusions and Relevance In a US...
GTS-21, an α7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function Immunobiology, Volume 225, Issue 3, 2020, Article 151950 Sana Douaoui,…, Yassine Amrani View PDFShow 3 more articles ...
(COPD). Pneumococcal and viral respiratory infections, such as influenza, pertussis, RSV and COVID 19, increase exacerbations, hospitalisation and mortality in patients with COPD [25], but vaccination helps to reduce risk of hospitalization, cardiovascular events, and exacerbations in COPD patients [...